• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Accolate (zafirlukast)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Accolate (zafirlukast)

  • Profile

Profile

Contact Information

Contact: AstraZeneca
Website: www.astrazeneca.com

Currently Enrolling Trials

    Show More

    General Information

    Accolate (zafirlukast) is a synthetic, selective peptide leukotriene receptor antagonist (LTRA).

    Accolate is specifically indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

    Accolate is supplied as a tablet for oral administration. Accolate should be taken at least 1 hour before or 2 hours after meals. The recommended dose of Accolate in adults and children 12 years and older is 20 mg twice daily.  The recommended dose of Accolate in children 5 through 11 years of age is 10 mg twice daily.

    Mechanism of Action

    Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. 

    Side Effects

    Adverse effects associated with the use of Accolate may include, but are not limited to, the following:

    • headache
    • diarrhea
    • nausea
    • pharyngitis
    • abdominal pain

    Clinical Trial Results

    The FDA approval of Accolate was based on three U.S. double-blind, randomized, placebo-controlled, 13-week clinical trials in 1,380 adults and children 12 years of age and older with mild-to-moderate asthma. Data demonstrated that Accolate improved daytime asthma symptoms, nighttime awakenings, mornings with asthma symptoms, rescue beta2-agonist use, FEV1, and morning peak expiratory flow rate. In these trials, improvement in asthma symptoms occurred within one week of initiating treatment with Accolate. 

    Additional Information

    For additional information regarding Accolate or asthma, please visit AstraZeneca's website.

    Approval Date: 1996-10-01
    Company Name: AstraZeneca
    Back to Listings

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing